Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Eisai Going Ahead with Global PIII for BAN2401 despite Aducanumab Setback
Eisai has launched a global PIII trial for its Alzheimer’s drug candidate BAN2401, the Japanese company said on March 22, just a day after it and its partner Biogen reported a big failure of aducanumab, another amyloid-targeting antibody. Topline data…
To read the full story
Related Article
- Eisai, Biogen Tout BAN2401’s Clinical Effect Regardless of APOE4 Mutation
October 29, 2018
- (Update) Eisai/Biogen Alzheimer’s Drug BAN2401 Slows Cognitive Decline by 30%
July 26, 2018
- Eisai/Biogen Say Alzheimer’s Candidate BAN2401 Delivered Positive Data at 18 Month Analysis
July 9, 2018
- Eisai/Biogen’s Alzheimer’s Candidate BAN2401 Disappoints in PII
December 25, 2017
BUSINESS
- Eylea Biosimilar Supply Curbed amid Originator Disruption
April 14, 2026
- Novartis, JSH Begin Project to Address Regional Gaps in Hematology Care
April 14, 2026
- Nxera to Receive US$22.5 Million Milestone as Schizophrenia Drug Enters PII
April 14, 2026
- Itochu Unit to Import Sodium, Potassium Chloride from Germany
April 14, 2026
- JCR Launches PIII Dose Comparison Study of Growject in Japan
April 14, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…